We also demonstrated the protective role of cardiomyocyte-specific knockout and pharmacological inhibition of YOD1 against myocardial hypertrophy, suggesting that cardiac-specific therapy targeting YOD1 may be an attractive strategy for the treatment of cardiac hypertrophy. Here, YOD1 is linked to cardiac hypertrophy.